AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10434214 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulse oximeter (Criticare 504) with averaging time set at 12 seconds
Number of subjects: 603
Study 10434214 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulse oximeter (Criticare 504) with averaging time set at 21 seconds
Number of subjects: 603
Study 7606610 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bacitracin zinc (BAC)
Number of subjects: 426
Study 7606610 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin sulfate, bacitracin zinc, and polymyxin B sulfate combination (NEO)
Number of subjects: 426
Study 7606610 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine (SIL)
Number of subjects: 426
Study 7606610 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum (PTR)
Number of subjects: 426
Study 2141773 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (50 or 100 micrograms/kg) or Sufentanil (10, 20, or 30 micrograms/kg)
Number of subjects: 80
Study 2141773 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil in one of four doses: 30 micrograms/kg as a single dose, 10 micrograms/kg plus infusion 0.05 microgram.kg‐1.min‐1, 20 micrograms/kg plus infusion 0.1 microgram.kg‐1.min‐1, or 40 micrograms/kg plus infusion 0.2 microgram.kg‐1.min‐1
Number of subjects: 80
Study 91901 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provided by specially trained nurses at the work site
Number of subjects: 457
Study 91901 — intervention group
Group type: COMPARATOR
Intervention: Care provided by family doctor
Number of subjects: 457
Study 31679474 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week circuit strength training (mixed typical resistance training and power training)
Number of subjects: 25
Study 31679474 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 25
Study 31199592 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate caloric restriction (250 kcal)
Number of subjects: 88
Study 31199592 — intervention group
Group type: EXPERIMENTAL
Intervention: High caloric restriction (600 kcal)
Number of subjects: 88
Study 31199592 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction with aerobic exercise
Number of subjects: 88
Study 31199592 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise alone
Number of subjects: 88
Study 27798731 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive strategy targeting LDL-C of 70 mg/dL and BP of 120/70 mmHg
Number of subjects: 97
Study 27798731 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy targeting LDL-C of 100 mg/dL and BP of 140/90 mmHg
Number of subjects: 97
Study 25873267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 312
Study 25873267 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D analog
Number of subjects: 312
Study 23813302 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV027
Number of subjects: 0
Study 20696677 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DP)
Number of subjects: 90
Study 20696677 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus carboplatin (DC)
Number of subjects: 90
Study 20696677 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 90
Study 19233764 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive direct coronary artery bypass (MIDCAB)
Number of subjects: 54
Study 19233764 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 54
Study 17965863 — intervention group
Group type: EXPERIMENTAL
Intervention: Azygos vein preserved (Group A)
Number of subjects: 96
Study 17965863 — intervention group
Group type: COMPARATOR
Intervention: Azygos vein ligated (Group B)
Number of subjects: 96
Study 15367055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (75 mg)
Number of subjects: 11
Study 15367055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11339590 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 17
Study 11339590 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating deep sclerectomy (NPDS) without collagen implants
Number of subjects: 17
Study 9848530 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) therapy with bioabsorbable polyglactin 910 barriers
Number of subjects: 26
Study 10085713 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia (CC)
Number of subjects: 122
Study 10085713 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BC)
Number of subjects: 122
Study 1863945 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of famotidine nightly for four to eight weeks
Number of subjects: 160
Study 1863945 — intervention group
Group type: COMPARATOR
Intervention: 300 mg of ranitidine nightly for four to eight weeks
Number of subjects: 160
Study 1863945 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of famotidine nightly during six-month maintenance treatment
Number of subjects: 160
Study 1863945 — intervention group
Group type: COMPARATOR
Intervention: 150 mg of ranitidine nightly during six-month maintenance treatment
Number of subjects: 160
Study 6849826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg twice weekly for 1 year)
Number of subjects: 61
Study 6849826 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy (twice-monthly phlebotomies of 400 ml whole blood for 1 year)
Number of subjects: 61
Study 6849826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 61
Study 6849826 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 61
Study 31525168 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Supplementation (PRO; 28.7 g casein protein)
Number of subjects: 60
Study 31525168 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate Placebo (PLA)
Number of subjects: 60
Study 31525168 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Supplementation (PRO)
Number of subjects: 60
Study 30326527 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (150% of habitual PA)
Number of subjects: 15
Study 30326527 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW (50% of habitual PA)
Number of subjects: 15
Study 30326527 — intervention group
Group type: COMPARATOR
Intervention: HABITUAL (100% of habitual PA)
Number of subjects: 15
Study 26754626 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan)
Number of subjects: 8399
Study 26754626 — intervention group
Group type: COMPARATOR
Intervention: Known diabetes mellitus (HbA1c ≥ 6.5%)
Number of subjects: 8399
Study 26754626 — intervention group
Group type: COMPARATOR
Intervention: Undiagnosed diabetes mellitus (HbA1c > 6.5%)
Number of subjects: 8399
Study 26754626 — intervention group
Group type: COMPARATOR
Intervention: Pre-diabetes mellitus (HbA1c 6.0%-6.4%)
Number of subjects: 8399
Study 26754626 — intervention group
Group type: COMPARATOR
Intervention: No diabetes mellitus (HbA1c < 6.0%)
Number of subjects: 8399
Study 24555542 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to shop for healthful foods
Number of subjects: 0
Study 24555542 — intervention group
Group type: COMPARATOR
Intervention: Motivation to shop for products based on taste
Number of subjects: 0
Study 22463472 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS) education
Number of subjects: 36
Study 22463472 — intervention group
Group type: COMPARATOR
Intervention: Standard hypoglycemia education (Control)
Number of subjects: 36
Study 20198424 — intervention group
Group type: COMPARATOR
Intervention: 15 mg lansoprazole daily
Number of subjects: 41
Study 20198424 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole and 300 mg rebamipide daily
Number of subjects: 41
Study 18291396 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (n = 14) combined with fentanyl 1 microg/kg
Number of subjects: 26
Study 18291396 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (n = 12) 1 microg/kg for 10 minutes, followed by 0.2 to 0.5 microg/kg/min
Number of subjects: 26
Study 15746835 — intervention group
Group type: EXPERIMENTAL
Intervention: High-almond diet (20% of total energy from almonds)
Number of subjects: 16
Study 15746835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-almond diet (10% of total energy from almonds)
Number of subjects: 16
Study 15746835 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0% of total energy from almonds)
Number of subjects: 16
Study 15746835 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond intake (overall)
Number of subjects: 16
Study 15746835 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond intake (dose-response effect)
Number of subjects: 16
Study 14518160 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (up to 400 mg/day)
Number of subjects: 15
Study 14518160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10380063 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-day titration group to 150 mg/day
Number of subjects: 0
Study 10380063 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-day titration group to 200 mg/day
Number of subjects: 0
Study 10380063 — intervention group
Group type: COMPARATOR
Intervention: 10-day titration group
Number of subjects: 0
Study 9408278 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (primary treatment for cutaneous malignant melanoma)
Number of subjects: 132
Study 9408278 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective lymphadenectomy with identification of the sentinel node
Number of subjects: 132
Study 9408278 — intervention group
Group type: COMPARATOR
Intervention: Elective lymph node dissection
Number of subjects: 132
Study 8228191 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (enalapril or lisinopril 20 mg once a day)
Number of subjects: 75
Study 8228191 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists (nifedipine 20 mg twice a day or lacidipine 4 mg once a day)
Number of subjects: 75
Study 2937811 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg/d
Number of subjects: 264
Study 2937811 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 3,900 mg/d
Number of subjects: 264
Study 2937811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 2937811 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 100 mg/d
Number of subjects: 264
Study 2937811 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 50 mg/d
Number of subjects: 264
Study 30641852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Number of subjects: 0
Study 30641852 — intervention group
Group type: COMPARATOR
Intervention: Fusion surgery
Number of subjects: 0
Study 28854851 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling using A-B-C technique
Number of subjects: 40
Study 27503012 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan combined with leflunomide (20 mg/d)
Number of subjects: 400
Study 27503012 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan combined with clopidogrel (50 mg/d)
Number of subjects: 400
Study 27503012 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 400
Study 24549212 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI 1 day after LH rise
Number of subjects: 412
Study 24549212 — intervention group
Group type: COMPARATOR
Intervention: IUI 2 days after LH rise
Number of subjects: 412
Study 22549300 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients with impaired left ventricular function
Number of subjects: 7865
Study 22549300 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients with three or more comorbidities
Number of subjects: 7865
Study 22549300 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort of heart failure patients
Number of subjects: 7865
Study 22549300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk women under 50 years old
Number of subjects: 7865
Study 22549300 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk octogenarian males
Number of subjects: 7865
Study 19347878 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17460947 — intervention group
Group type: EXPERIMENTAL
Intervention: BB536 yogurt (2 x 100 g per day for 14 weeks)
Number of subjects: 40
Study 17460947 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt (2 x 100 g per day for 14 weeks)
Number of subjects: 40
Study 17460947 — intervention group
Group type: EXPERIMENTAL
Intervention: BB536 yogurt
Number of subjects: 40
Study 17460947 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 40
Study 16246662 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria
Number of subjects: 58
Study 16246662 — intervention group
Group type: COMPARATOR
Intervention: No Laminaria
Number of subjects: 58
Study 12475469 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip (HG) for 2 min during impending syncope
Number of subjects: 19
Study 12475469 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 19
Study 7966027 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH (450 iu) injected i.m. on day 2 of the cycle
Number of subjects: 12
Study 7966027 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH (225 iu) injected on the day the dominant follicle was 14-15 mm in diameter
Number of subjects: 12
Study 7966027 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml 0.9% normal saline)
Number of subjects: 12
Study 3331977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg orally) in normal children (NC)
Number of subjects: 43
Study 3331977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg orally) in short children (SC)
Number of subjects: 43
Study 3331977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg orally) in normal adults (NA)
Number of subjects: 43
Study 3331977 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine (60 mg orally) in short children (SC) vs Insulin hypoglycaemia (IH)
Number of subjects: 43
Study 29028448 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month behavioral intervention
Number of subjects: 30
Study 29028448 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight (NW) controls
Number of subjects: 30
Study 29028448 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 30
Study 28096254 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prescription (phenoxymethylpenicillin used in 67% of cases)
Number of subjects: 401
Study 28096254 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to hospital
Number of subjects: 401
Study 25762226 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance programme consisting of 2 hours (1 hour individually tailored exercise training and 1 hour education programme) every 3 months for 1 year
Number of subjects: 110
Study 25762226 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 110
Study 22806487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaizey score
Number of subjects: 80
Study 22806487 — intervention group
Group type: EXPERIMENTAL
Intervention: Wexner score
Number of subjects: 80
Study 22806487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Incontinence Quality of Life Scale (FIQL)
Number of subjects: 80
Study 21712486 — intervention group
Group type: EXPERIMENTAL
Intervention: LCS101 (2 g capsules thrice daily)
Number of subjects: 65
Study 21712486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 18027055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 200
Study 18027055 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet fundoplication
Number of subjects: 200
Study 16802490 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 microg/kg
Number of subjects: 63
Study 16802490 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 microg/kg
Number of subjects: 63
Study 16802490 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and Fentanyl
Number of subjects: 63
Study 15609595 — intervention group
Group type: EXPERIMENTAL
Intervention: Guben Xiaoliu Capsule (GXC) plus chemotherapy (CT) in Group A
Number of subjects: 198
Study 15609595 — intervention group
Group type: EXPERIMENTAL
Intervention: Guben Xiaoliu Capsule (GXC) alone in Group B
Number of subjects: 198
Study 15609595 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone in Group C
Number of subjects: 198
Study 10972447 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking abstinence (n = 16)
Number of subjects: 21
Study 10972447 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking (n = 5)
Number of subjects: 21
Study 9049577 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg)
Number of subjects: 0
Study 9049577 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 0
Study 9049577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8315146 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium level of structure (categorized words presented in randomized order)
Number of subjects: 0
Study 8315146 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition memory
Number of subjects: 0
Study 8315146 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal detection analysis (d')
Number of subjects: 0
Study 8315146 — intervention group
Group type: COMPARATOR
Intervention: High and low structured material
Number of subjects: 0
Study 2884197 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms/hr i.v. for 48 hrs)
Number of subjects: 49
Study 2884197 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin (0.1 U/min i.v. for 48 hrs)
Number of subjects: 49
Study 2884197 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms/hr i.v. for 7 days after initial treatment)
Number of subjects: 49
Study 2884197 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after initial treatment)
Number of subjects: 49
Study 31136042 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (5000 IU daily for 80 days)
Number of subjects: 151
Study 31136042 — intervention group
Group type: COMPARATOR
Intervention: Stoss therapy (100,000 IU weekly for 4 weeks)
Number of subjects: 151
Study 30248301 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Interval Training (HIIT)
Number of subjects: 36
Study 30248301 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 36
Study 30248301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (PRT + HIIT)
Number of subjects: 36
Study 30248301 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 36
Study 27882535 — intervention group
Group type: EXPERIMENTAL
Intervention: KingVision™
Number of subjects: 480
Study 27882535 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq™
Number of subjects: 480
Study 27882535 — intervention group
Group type: EXPERIMENTAL
Intervention: A.P. Advance™ MAC
Number of subjects: 480
Study 27882535 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 480
Study 25887978 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a magnifying loupe (x2.5)
Number of subjects: 182
Study 25887978 — intervention group
Group type: COMPARATOR
Intervention: No use of a magnifying loupe
Number of subjects: 182
Study 23138409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic flamingo exercise (one-leg standing with eyes open for a total of 1 min, three times a day for 6 months)
Number of subjects: 865
Study 23138409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic flamingo exercise
Number of subjects: 865
Study 23138409 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 865
Study 21478808 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session panretinal photocoagulation (SS-PRP)
Number of subjects: 40
Study 21478808 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-session panretinal photocoagulation (MS-PRP)
Number of subjects: 40
Study 19263185 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted cow's milk-based formula
Number of subjects: 6209
Study 19263185 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula
Number of subjects: 6209
Study 19263185 — intervention group
Group type: EXPERIMENTAL
Intervention: Banked human milk
Number of subjects: 6209
Study 19263185 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breast-fed in the hospital
Number of subjects: 6209
Study 19263185 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk-based formula exposure
Number of subjects: 6209
Study 19263185 — intervention group
Group type: EXPERIMENTAL
Intervention: Early regular daily feeding with cow's milk-based formula
Number of subjects: 6209
Study 17913505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookwire technique (Group A)
Number of subjects: 50
Study 17913505 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-guided surgery (Group B)
Number of subjects: 50
Study 17913505 — intervention group
Group type: COMPARATOR
Intervention: Finger palpation (control for both groups)
Number of subjects: 50
Study 15750987 — intervention group
Group type: EXPERIMENTAL
Intervention: on-line HFR
Number of subjects: 6
Study 15750987 — intervention group
Group type: COMPARATOR
Intervention: pre-cartridge
Number of subjects: 6
Study 11581005 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized DHEA, 25 mg/day for 12 months
Number of subjects: 20
Study 11581005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9152127 — intervention group
Group type: EXPERIMENTAL
Intervention: White infants
Number of subjects: 4099
Study 9152127 — intervention group
Group type: EXPERIMENTAL
Intervention: Black infants
Number of subjects: 4099
Study 9152127 — intervention group
Group type: COMPARATOR
Intervention: Race as a factor
Number of subjects: 4099
Study 8267129 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (410.5 mg/day, SD = 45.8)
Number of subjects: 39
Study 8267129 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (24.8 mg/day, SD = 5.5)
Number of subjects: 39
Study 8267129 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 39